Malaysia-based Yakin Medic plans to raise RM100 million from an IPO on the Catalist board of the Singapore Exchange , reports The Edge Malaysia, The Star, The Sun and various other Malaysian papers.
The IPO, targeted for 4Q this year or early 2026, is part of its broader growth bid.
Yakin Medic is described as a provider of active live stem cell therapies.
The company has attracted investment firm MCI Capital to be a cornerstone investor, and Singapore-based Evolve Capital will be the sponsor and IPO manager.
